CN109069579A - 环状三肽用于改善细胞能量代谢的用途 - Google Patents
环状三肽用于改善细胞能量代谢的用途 Download PDFInfo
- Publication number
- CN109069579A CN109069579A CN201680067857.2A CN201680067857A CN109069579A CN 109069579 A CN109069579 A CN 109069579A CN 201680067857 A CN201680067857 A CN 201680067857A CN 109069579 A CN109069579 A CN 109069579A
- Authority
- CN
- China
- Prior art keywords
- peptide
- way
- egg mother
- mother cell
- feec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000006567 cellular energy metabolism Effects 0.000 title claims abstract description 8
- 125000004122 cyclic group Chemical group 0.000 title description 5
- 210000000130 stem cell Anatomy 0.000 claims abstract description 96
- 230000004720 fertilization Effects 0.000 claims abstract description 39
- 238000000338 in vitro Methods 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 24
- 230000035800 maturation Effects 0.000 claims abstract description 22
- 108010069514 Cyclic Peptides Proteins 0.000 claims abstract description 10
- 102000001189 Cyclic Peptides Human genes 0.000 claims abstract description 10
- 102000006495 integrins Human genes 0.000 claims abstract description 10
- 108010044426 integrins Proteins 0.000 claims abstract description 10
- 230000008929 regeneration Effects 0.000 claims abstract 4
- 238000011069 regeneration method Methods 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 61
- 210000001161 mammalian embryo Anatomy 0.000 claims description 52
- 210000000287 oocyte Anatomy 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 29
- 230000035935 pregnancy Effects 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 210000002459 blastocyst Anatomy 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 230000009027 insemination Effects 0.000 claims description 10
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 9
- 208000000995 spontaneous abortion Diseases 0.000 claims description 9
- 210000001109 blastomere Anatomy 0.000 claims description 7
- 230000013020 embryo development Effects 0.000 claims description 7
- 230000035558 fertility Effects 0.000 claims description 7
- 208000015994 miscarriage Diseases 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 208000037280 Trisomy Diseases 0.000 claims description 4
- 208000036878 aneuploidy Diseases 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 231100001075 aneuploidy Toxicity 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012606 in vitro cell culture Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 abstract description 4
- 210000002308 embryonic cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 28
- 210000003470 mitochondria Anatomy 0.000 description 21
- 238000011160 research Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 238000012546 transfer Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 15
- 230000006872 improvement Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 102000002322 Egg Proteins Human genes 0.000 description 10
- 108010000912 Egg Proteins Proteins 0.000 description 10
- 230000031864 metaphase Effects 0.000 description 10
- 210000004681 ovum Anatomy 0.000 description 10
- 230000019100 sperm motility Effects 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000011721 B6CBAF1 mouse Methods 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 210000001700 mitochondrial membrane Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 210000003934 vacuole Anatomy 0.000 description 6
- 206010000210 abortion Diseases 0.000 description 5
- 231100000176 abortion Toxicity 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004508 polar body Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 102000012355 Integrin beta1 Human genes 0.000 description 3
- 108010022222 Integrin beta1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000013035 dynein heavy chain Human genes 0.000 description 2
- 108060002430 dynein heavy chain Proteins 0.000 description 2
- 230000008143 early embryonic development Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- -1 molecule Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-alpha-acetyl-L-glutamate Natural products CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000000979 axoneme Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000000056 copulatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- ILLHQJIJCRNRCJ-UHFFFAOYSA-N dec-1-yne Chemical compound CCCCCCCCC#C ILLHQJIJCRNRCJ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 230000016853 telophase Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B21/00—Tying-up; Shifting, towing, or pushing equipment; Anchoring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B63—SHIPS OR OTHER WATERBORNE VESSELS; RELATED EQUIPMENT
- B63B—SHIPS OR OTHER WATERBORNE VESSELS; EQUIPMENT FOR SHIPPING
- B63B21/00—Tying-up; Shifting, towing, or pushing equipment; Anchoring
- B63B2021/003—Mooring or anchoring equipment, not otherwise provided for
- B63B2021/004—Quick release elements in mooring connections
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Birds (AREA)
- Ophthalmology & Optometry (AREA)
- Combustion & Propulsion (AREA)
- Mechanical Engineering (AREA)
- Ocean & Marine Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
参数 | 对照 | FEE | P | |
VAP(μm/s) | 81.0±16.8 | 86.3±13.7 | 0.008 | 7% |
VSL(μm/s) | 67.3±16.7 | 71.8±15.3 | 0.048 | 7% |
VCL(μm/s) | 137.5±26.7 | 148.0±26.6 | <0.0001 | 8% |
ALH(μm) | 6.1±1.3 | 6.6±1.3 | 0.002 | 8% |
BCF(Hz) | 32.7±3.4 | 33.0±3.9 | NS | - |
STR(%) | 85.8±11.4 | 84.9±10.0 | NS | - |
LIN(%) | 51.1±12.6 | 50.9±12.2 | NS | - |
超活化 | 12.3±9.7 | 15.9±11.6 | 0.009 | 29% |
Claims (24)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1558899A FR3041260B1 (fr) | 2015-09-21 | 2015-09-21 | Utilisation d'un tripeptide cyclique pour stimuler l'activite mitochondriale de cellules |
FR1558899 | 2015-09-21 | ||
PCT/EP2016/072476 WO2017050854A1 (fr) | 2015-09-21 | 2016-09-21 | Utilisation d'un tripeptide cyclique pour ameliorer le metabolisme energetique cellulaire |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109069579A true CN109069579A (zh) | 2018-12-21 |
CN109069579B CN109069579B (zh) | 2022-04-29 |
Family
ID=56263743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680067857.2A Active CN109069579B (zh) | 2015-09-21 | 2016-09-21 | 环状三肽用于改善细胞能量代谢的用途 |
Country Status (16)
Country | Link |
---|---|
US (1) | US11278589B2 (zh) |
EP (1) | EP3352775B1 (zh) |
JP (1) | JP6918804B2 (zh) |
KR (1) | KR20180133373A (zh) |
CN (1) | CN109069579B (zh) |
AU (1) | AU2016325378B2 (zh) |
BR (1) | BR112018005457A8 (zh) |
CA (1) | CA2998747A1 (zh) |
ES (1) | ES2969739T3 (zh) |
FR (1) | FR3041260B1 (zh) |
HK (1) | HK1258383A1 (zh) |
IL (1) | IL258178B2 (zh) |
MA (1) | MA42928B1 (zh) |
RU (1) | RU2737116C2 (zh) |
WO (1) | WO2017050854A1 (zh) |
ZA (1) | ZA201802132B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019097290A1 (en) * | 2017-11-15 | 2019-05-23 | Aratinga.Bio | Enhancement of biologics production in cell culture systems by fertilin-derived peptides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150051152A1 (en) * | 2003-11-19 | 2015-02-19 | Universite Paris 13 | Peptide increasing fusiogenic capacity of a gamete |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20040255A1 (it) * | 2004-02-17 | 2004-05-17 | Univ Degli Studi Milano | Sostanze ad attivita' antiangiogenica |
RU2005128993A (ru) * | 2005-09-08 | 2007-03-20 | Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) | Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний |
-
2015
- 2015-09-21 FR FR1558899A patent/FR3041260B1/fr active Active
-
2016
- 2016-09-21 MA MA42928A patent/MA42928B1/fr unknown
- 2016-09-21 JP JP2018534019A patent/JP6918804B2/ja active Active
- 2016-09-21 CN CN201680067857.2A patent/CN109069579B/zh active Active
- 2016-09-21 KR KR1020187011126A patent/KR20180133373A/ko not_active Application Discontinuation
- 2016-09-21 IL IL258178A patent/IL258178B2/en unknown
- 2016-09-21 RU RU2018114660A patent/RU2737116C2/ru active
- 2016-09-21 US US15/761,825 patent/US11278589B2/en active Active
- 2016-09-21 AU AU2016325378A patent/AU2016325378B2/en active Active
- 2016-09-21 WO PCT/EP2016/072476 patent/WO2017050854A1/fr active Application Filing
- 2016-09-21 ES ES16775555T patent/ES2969739T3/es active Active
- 2016-09-21 EP EP16775555.2A patent/EP3352775B1/fr active Active
- 2016-09-21 CA CA2998747A patent/CA2998747A1/fr active Pending
- 2016-09-21 BR BR112018005457A patent/BR112018005457A8/pt active Search and Examination
-
2018
- 2018-04-03 ZA ZA2018/02132A patent/ZA201802132B/en unknown
-
2019
- 2019-01-17 HK HK19100781.2A patent/HK1258383A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150051152A1 (en) * | 2003-11-19 | 2015-02-19 | Universite Paris 13 | Peptide increasing fusiogenic capacity of a gamete |
Non-Patent Citations (4)
Title |
---|
A ZIYYAT等: "Cyclic FEE peptide increases human gamete fusion and potentiates its RGD-induced inhibition", 《HUM REPROD.》 * |
R.ROTIVAL等: "Comprehensive determination of the cyclic FEE peptide chemical stability in solution", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
VIRGINIE BARRAUD-LANGE等: "Cyclic QDE peptide increases fertilization rates and provides healthy pups in mouse", 《FERTILITY AND STERILITY》 * |
黄睿 等: "人卵和胚胎线粒体ATP合酶表达的研究", 《华中科技大学学报(医学版)》 * |
Also Published As
Publication number | Publication date |
---|---|
BR112018005457A8 (pt) | 2022-11-08 |
IL258178A (en) | 2018-05-31 |
RU2737116C2 (ru) | 2020-11-24 |
IL258178B2 (en) | 2024-03-01 |
MA42928A (fr) | 2018-08-01 |
RU2018114660A3 (zh) | 2020-03-02 |
AU2016325378B2 (en) | 2020-08-20 |
CN109069579B (zh) | 2022-04-29 |
MA42928B1 (fr) | 2024-01-31 |
EP3352775A1 (fr) | 2018-08-01 |
US20180264075A1 (en) | 2018-09-20 |
EP3352775B1 (fr) | 2023-11-01 |
CA2998747A1 (fr) | 2017-03-30 |
HK1258383A1 (zh) | 2019-11-08 |
JP2018536013A (ja) | 2018-12-06 |
ES2969739T3 (es) | 2024-05-22 |
FR3041260A1 (fr) | 2017-03-24 |
RU2018114660A (ru) | 2019-10-23 |
ZA201802132B (en) | 2019-09-25 |
EP3352775C0 (fr) | 2023-11-01 |
BR112018005457A2 (pt) | 2018-10-09 |
KR20180133373A (ko) | 2018-12-14 |
WO2017050854A1 (fr) | 2017-03-30 |
AU2016325378A1 (en) | 2018-04-19 |
IL258178B1 (en) | 2023-11-01 |
JP6918804B2 (ja) | 2021-08-11 |
FR3041260B1 (fr) | 2020-10-02 |
US11278589B2 (en) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moore et al. | The developing human E-book | |
De Jonge | Biological basis for human capacitation—revisited | |
Carlson | Human Embryology and Developmental Biology: with STUDENT CONSULT Online Access | |
Campbell et al. | The effect of monosaccharide sugars and pyruvate on the differentiation and metabolism of sheep granulosa cells in vitro | |
Gambera et al. | Intracytoplasmic sperm injection and pregnancy with decapitated sperm | |
CN110295143A (zh) | 有关胚胎移植延迟和使用外周血单核细胞的体外受精方法 | |
Leroy et al. | Maternal metabolic health and fertility: we should not only care about but also for the oocyte! | |
Enders et al. | Differentiation of blastocysts derived from in vitro-fertilized rhesus monkey ova | |
Paternot et al. | The spatial arrangement of blastomeres at the 4-cell stage and IVF outcome | |
CN109069579A (zh) | 环状三肽用于改善细胞能量代谢的用途 | |
DE60133644T2 (de) | Embryonale stammzellen abkünftig aus affen | |
Yang et al. | Effects of Yu Linzhu on ovarian function and oocyte mitochondria in natural aging mice | |
CN108700494A (zh) | 鉴定用于实现哺乳动物受精的途径和授精时期的方法 | |
Jiang et al. | Effect of You Gui Wan on mouse sperm fertilising ability in vivo and in vitro | |
Mohsin | Fertilization and Embryonic Development after Oral Administration of Lepidium meyenii (Maca) and Glycyrrhiza glabra Crude Aqueous Extract in Mice | |
CN110205283A (zh) | 一种诱导人羊膜上皮细胞向视网膜色素上皮细胞分化的方法及其应用 | |
Combelles et al. | Determinants of oocyte quality: impact on in vitro fertilization failures | |
Liu et al. | Foxo4-dri alleviates age-related testosterone secretion insufficiency via targeting senescent leydig cells in aged mice | |
Varghese et al. | Current trends in evaluation of sperm function: in vitro selection and manipulation of male gametes for assisted conception | |
Zambelli et al. | P-216 Low meiotic progression rates in oocytes from older women are due to impaired mitochondrial metabolism | |
Batten et al. | Fine structural analysis of the effect of trypan blue on the visceral endoderm of the mouse egg cylinder | |
Fazliogullari | Developmental Toxicity Using the Rat Whole Embryo Culture | |
Ye | Addition of endothelin-1 to culture medium promotes human oocyte maturation | |
CN110106147A (zh) | 一种诱导人羊膜上皮细胞向视网膜感光细胞分化的方法及其应用 | |
CN109254154A (zh) | 人cd147的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Paris France Patentee after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Patentee after: University of Western dais, Paris Patentee after: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Patentee after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Address before: Paris France Patentee before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Patentee before: University of Paris Patentee before: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Patentee before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220817 Address after: Paris France Patentee after: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Patentee after: University of Paris Patentee after: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Patentee after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Address before: Paris France Patentee before: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Patentee before: UNIVERSITE PARIS DESCARTES Patentee before: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Patentee before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
|
TR01 | Transfer of patent right |